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Abstract
Macrophages, which are found in all tissues, are an essential component of the innate immune system, and they
play important roles in host defense, inflammation, autoimmune diseases as well as cancer. Functionally,
macrophages are classified into two types: classically-activated M1 macrophages and alternatively-activated M2
macrophages. The M1 macrophages typically produce high levels of proinflammatory cytokines and chemokines,
whereas M2 macrophages show an efficient phagocytic and scavenging activity. Because the phenotypes of
polarized M1 and M2 macrophages can be induced, and reversed to some extent, by various signals, different
phases of many diseases are associated with dynamic changes in the balance between M1 and M2 macrophages.
The colony-stimulating factor 1 receptor (CSF-1R), a class III receptor tyrosine kinase, sustains the survival,
proliferation and differentiation of monocytes and macrophages. Drugging CSF-1R may be the only way to target
macrophages within a pathological context. However, CSF-1R-dependent signals may be either positive or
detrimental depending on the disease and even on the phase of disease. The role of CSF-1R and its ligands, the
colony-stimulating factor-1 and interleukin-34, in macrophages with respect to the pathogenesis of several
inflammatory or neoplastic diseases has been reviewed previously. This review will focus specifically on evidences
obtained about the role of CSF-1R in macrophage polarization in the context of physiological as well as pathological
conditions including inflammation and cancer. The possibility to target CSF-1R, using the several inhibitors already
available, for the treatment of inflammatory diseases as well as cancer will be also discussed.
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Macrophage Polarization
Monocytes are released from the bone marrow (BM) into the
circulation and migrate into almost every tissue of the body, where
they differentiate into mature macrophages. Macrophages include liver
Kupffer cells, brain microglia, lung alveolar macrophages, peritoneal
macrophages, adipose tissue macrophages and bone osteoclasts [1].
Monocytes/macrophages are critical effectors and regulators of a
number of patho-physiological processes within innate and adaptive
immunity, systemic metabolism, hematopoiesis, angiogenesis,
reproduction and cancer [2-4]. Macrophages are highly plastic cells
that change phenotype to acquire different skills depending on the
microenvironmental stimuli to which they are exposed.
Microbial stimuli, including toll-like receptor (TLR) ligands, the
prototype of which is lipopolysaccharide (LPS), and Th1 cytokines like
interferon gamma (IFNγ) induce the “classical” macrophage activation
(M1-like macrophage polarization). These cells show increased
expression of inflammatory cytokines, chemokines, and reactive
nitrogen/oxygen intermediates. M1 cells preferentially promote Th1
effector response, possess anti-microbial ability, protect against various
types of bacteria and viruses, and display tumoricidal functions. On
the other hand, an “alternative” activation (M2-like macrophage
polarization) may be elicited by Interleukin (IL)-4 and IL-13 (M2a),
immune complexes (M2b), the anti-inflammatory cytokine IL-10
(M2c), transforming growth factor β (TGFβ) and/or glucocorticoids.
Alternatively activated macrophages typically show increased
expression of scavenging receptors and scavenging activity, reduced
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expression of inflammatory cytokines, and metabolize arginine to
ornithine preferentially via arginase. Moreover, these cells are mainly
devoted to tissue repair-remodeling functions and are important for
the clearance of parasite infection. Additionally, M2 cells may also be
involved in tumor promotion. M1/M2 polarization thus mirrors
Th1/Th2 polarization and mediates Th1/Th2 immune responses.
Nevertheless, phenotypic and functional abilities of M1 and M2
macrophages are not rigidly segregated, rather representing a
continuum ranging from M1 to M2. Furthermore, mouse and human
macrophages are distinct with respect to the expression levels of some
markers of polarization [5-8].
The Colony-Stimulating Factor-1 Receptor in
Macrophage Development and Differentiation
The colony-stimulating factor-1 receptor (CSF-1R, also known as
macrophage colony-stimulating factor receptor, M-CSFR) is a
homodimeric type III receptor tyrosine kinase that is encoded by the
c-fms proto-oncogene. It contains an extracellular ligand-binding
domain, a transmembrane domain, and an intracellular domain that
contains a split kinase domain. CSF-1R regulates the differentiation of
myeloid progenitors into heterogeneous populations of monocytes,
macrophages, dendritic cells (DC) and bone-resorbing osteoclasts [9].
Moreover, activated CSF-1R promotes the survival, proliferation,
differentiation and chemotaxis of differentiated macrophages. The
known CSF-1R ligands are CSF-1 (also known as macrophage colony-
stimulating factor, M-CSF) and IL-34 [10,11]. Although there are
significant differences in their signaling through CSF-1R, it is primarily
the different expression of CSF-1 and IL-34 in vivo that controls their
different spatiotemporal action through CSF-1R. Moreover, CSF-1
exists in several isoforms, which show different, yet sometimes
overlapping, roles: a secreted glycoprotein and a secreted proteoglycan,
both of which circulate, and a membrane-spanning, cell-surface
glycoprotein. The amount of circulating CSF-1 is humorally-regulated.
Nevertheless, CSF-1 serum concentration is around 10 ng/ml in
healthy people [12]. By contrast, IL-34 is not detectable in the
circulation of healthy individuals, so that IL-34 action is likely
restricted to the microenvironments where it is released [11]. CSF-1R
appears to be the only receptor for CSF-1, because all of the CSF-1
deficiency phenotypes are exhibited by CSF-1R-deficient mice [13]. On
the other hand, IL-34 acts also through the protein tyrosine
phosphatase-z receptor [14].
The biological activities of CSF-1R have been extensively
characterized, especially those following its engagement with CSF-1 in
myeloid cells. CSF-1 binding leads to CSF-1R auto-phosphorylation on
many tyrosine residues. Eight tyrosines are known to be
phosphorylated in the intracellular domain of the activated murine
CSF-1R proto-oncoprotein/oncoprotein: Tyr-559 and Tyr-544, in the
juxtamembrane domain, Tyr-697, Tyr-706, and Tyr-721 in the kinase
insert domain and Tyr-807, Tyr-921 and Tyr-974 in the carboxy-
terminal tail [11]. Phosphorylation of individual CSF-1R tyrosines
creates docking sites for several signaling molecules thus leading to the
activation of signaling pathways. It is well established that
phosphorylation of Tyr-559 determines the activation of Src-Family
Kinases and of the mitogen-activated protein kinase (MAPK)
extracellular-signal-regulated kinase (ERK) 5 (through Tyr-561 of
human CSF-1R that corresponds to Tyr-559 in the murine CSF-1R),
while phosphorylation of Tyr-721 activates phosphatidyl inositol 3-
kinase (PI3K). On the other hand, phosphorylation at different sites
including that of Tyr-807 activates the MAPK ERK1 and ERK2, while
recruitment of Grb2 by phosphorylated Tyr-921 or Tyr-697 may lead
to the activation of other signaling pathways [11].
Referring to the relationship of CSF-1R-elicited signals to
macrophage polarization, it is known that the PI3K pathway, which is
activated by CSF-1R, regulates M1/M2 activation programs in
macrophages [15]. Along this line, it was recently reported that
pTyr-721 signaling downregulates proinflammatory genes, including
IL-1β (a cytokine typically expressed by M1 polarized macrophages),
while upregulating the expression of the M2 genes coding for Arginase
(Arg1) and IL-10 [16]. Moreover, miR-21 emerged as a CSF-1-induced
pTyr-721- and PI3K-dependent product involved in the regulation of
macrophage activation. Indeed, miR-21 inhibition impairs the CSF-1-
dependent reduction of IL-1β expression. Besides suppressing the
proinflammatory phenotype in vitro, miR-21 attenuates the
recruitment of Ly6Chigh (i.e., inflammatory) monocytes to the
peritoneal cavity in response to LPS in vivo. Taken together, these
results indicated that pTyr-721 signaling suppresses the macrophage
proinflammatory phenotype [16].
Besides ligand-induced tyrosine phosphorylation, CSF-1R activity
may be regulated by ligand-induced down-regulation or down-
modulation that occurs by ectodomain shedding. In the latter scenario,
CSF-1R protein degradation follows protein kinase C activation by
TLR-activating molecules, such as LPS, or by IL including IL-4 and
IL-2 [17-19]. Whether CSF-1R down-modulation affects macrophage
plasticity and response to M1/M2-polarizing stimuli has not been
addressed. However, it should be noted that either M1- (LPS, IL-2) and
M2-like inducing agents (IL-4) are able to down-regulate CSF-1R [20].
Another important point that should be taken into consideration,
especially when thinking about the possible targeting of CSF-1R, is the
fact that CSF-1R signaling may be activated, in a ligand-independent
manner, following transactivation by other stimuli including
prostaglandin E2, a key mediator of immunity, inflammation and
cancer, following engagement to its G-protein-coupled E-prostanoid
receptors [21].
The essential role of CSF-1/CSF-1R axis in the development of most
tissue macrophages has been well-established using naturally
occurring csf1-deficient op/op mice [22,23] and csf1r knockout mice
[13]. Moreover, during early myeloid differentiation, CSF-1 synergizes
with other growth factors, including stem cell factor (SCF) and IL-3, to
generate, from hematopoietic stem cells, mononuclear phagocyte
progenitor cells [24,25]. The proliferation and differentiation of these
cells to monocytes and macrophages is then regulated by CSF-1 itself,
which also controls the survival, proliferation and function of fully
differentiated macrophages [24].
The role of CSF-1R in tissue development and homeostasis has been
extensively reviewed [26-29]. Recent reports identified a role for
CSF-1R in macrophage activation/polarization under physiological
conditions. Microglia, the macrophages resident in the central nervous
system (CNS), is absent in csf1r-deficient mice [30], while csf1-
deficient mice show decreased microglial numbers and IL34-deficient
mice an even more severe lack [31,32]. Increased levels of CSF-1
together with increased microglial cell number and activation are
found in many different CNS pathologies including tumors,
degenerative diseases and injuries [33,34]. To test the hypothesis that
increased CSF-1 levels impact on both microglial cell numbers and
phenotype in vivo, a mice model was developed that overexpresses csf1
in the glial fibrillary acidic protein (GFAP) compartment (i.e.
astrocytes) [35]. Compared with controls, csf1-overexpressing mice
harbor significantly greater numbers of microglia cells (i.e. CD11b+
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cells) in brain and increased microglia proliferation. Pharmacological
Inhibition of CSF-1R with PLX3397 (Table 1) promotes microglial
apoptosis and reverses the microglial increase observed in csf1-
overexpressing mice. CSF-1 overexpression does not promote basal
activation in vivo but causes defects in response to LPS. Indeed, when
several parameters linked to macrophage activation were measured ex
vivo in microglia from mice systemically-treated with LPS, csf1-
overexpressing mice were found to underexpress, when compared to
control mice, M1-type molecules such as IL-1β and iNos/NOS2 but
also the M2 marker IL-10. These results are at variance with several
reports indicating that CSF-1 acts synergistically with LPS to induce
the expression of several cytokines in monocytes/macrophages. In
order to explain these differences, the authors proposed that microglia
behaves differently from other macrophage populations on which most
of the studies are based [35].
In keeping with a primary role of CSF-1 in monocyte/macrophage
development, it was recently reported that endothelial cells that express
CSF-1 are able to support the growth of murine BM hematopoietic
cells [45]. Endothelial cells and macrophages are known to interact,
thereby contributing to the modulation of vascular function [29]. The
long-term co-culture of murine endothelial cells immortalized from
different tissues with murine hematopoietic cells (in the presence of
cytokines such as SCF, Flt3-L, IL-6, IL-3, thrombopoietin and vascular-
endothelial growth factor A) allows the development of colonies of
differentiated macrophages (F4/80+ and Mac1+ cells). Under the
above-described conditions, immortalized endothelial cells express the
membrane form of CSF-1, while cells of developed colonies express
CSF-1R. The functional contribution of CSF1/CSF1R in the expansion,
rather than the formation, of these colonies was established using the
CSF-1R inhibitor GW2580. Colony macrophages express high levels of
M2 markers including Arg1, CD206/Mrc1 and CD36, while no
detectable M1 markers (IL-12, IL-1, and tumor necrosis factor α,
TNFα) were found. However, whether CSF-1R was involved in M2
polarization was not addressed [45].
According to the fact that CSF-1 alone is able to sustain monocyte/
macrophage differentiation, the experimental characterization of
macrophage activation and functions has been performed mainly
using macrophages obtained through CSF-1-induced differentiation of
murine BM or human peripheral-blood monocytes (PBMC). In this
respect it should be taken into consideration that the use of human
recombinant CSF-1 (hrCSF-1) or of L929 cell-conditioned medium
(LCCM) as a source of CSF-1 [46] may lead to different outcomes.
Indeed, a different macrophage activation status may arise depending
on the source of CSF-1 used, as described for the response to A.
fumigatus, where hrCSF-1 exhibited a lower effect than LCCM in the
predisposition to M1 phenotype [47]. These differences are likely due
to the fact that LCCM contains, other than CSF-1, variable amounts of
several growth factors and cytokines, including granulocyte
macrophage colony-stimulating factor (GM-CSF) and type I
interferons, that can cause additional effects in subsequent activation
experiments [47,48].
Peritoneal macrophages (resident or elicited) from mice and GM-
CSF-cultured macrophages from murine BM are also widely used.
However, GM-CSF- and CSF-1-differentiated macrophages have
different transcriptomes [49] and GM-CSF and CSF-1 may promote
alone an M1 or an M2 phenotype, respectively [50,51]. In spite of this,
to refer to GM-CSF and CSF-1 as the cytokines responsible for the
prototypical M1 or M2 phenotype in not based on solid evidence [7].
Another important point is that CSF-1- and GM-CSF-differentiated
macrophages may react similarly to a further polarization induced by
IFNγ or IL-4+IL-13 [8,52]. In this respect, it has been recently shown
that the most robust M2 activation phenotype is induced by IL-4/
IL-10/TGFβ following differentiation with CSF-1 [53]. Indeed, flow
cytometry showed that the expression of the M2-like CD206 mannose
receptor as well as of other M2 markers (including the costimulatory
receptor CD273, the gene CiiTA, the class B scavenger receptor SRB1,
the mannose receptor CD206, the IL-1 receptor 2 (IL-1R2) and heme-
oxygenase (HO)-1) were best induced following differentiation with
CSF-1 rather than GM-CSF. On the other hand, CSF-1-differentiated
macrophages are capable to undergo a later polarization towards the
M1 phenotype [8]. While the costimulatory receptor CD86 was
elevated following LPS/IFNγ-induced M1 activation, with highest
expression on GM-CSF-differentiated macrophages, the expression of
the costimulatory receptor CD274 was elevated following M1
activation, but, surprisingly, was highest in CSF-1-differentiated cells.
Following IL-4/IL-10/TGFβ-induced M2 activation, the M1-associated
markers IL-1 and IL-23 dominated in GM-CSF-differentiated cells,
whereas CXCL10, CXCL11, IL-6, IL-12α and TNFα were higher in
CSF-1-differentiated M1 cells. Furthermore, CSF-1-differentiated cells,
that are often considered to be M2-polarized, expressed accordingly
higher levels of M2-associated IL-10, CCL14 and CD206, which were
retained following secondary M1 stimulation. These results indicate
that, while M1 and M2 activation states can be induced irrespective of
a rigid segregation of differentiation signals, it is the balance of these
signals (growth factors) which defines the ultimate macrophage
activation phenotype [53].
CSF-1R is also able to interfere with IL-32-induced macrophage
polarization [54]. IL-32 promotes the differentiation of monocytes into
macrophage-like cells and induces the production of various cytokines
including TNFα and IL-8, so that it is considered an inducer of M1-
like macrophages [55,56]. While investigating how the co-treatment
with CSF-1 and IL-32 affects the M1/M2 ratio, it was found that, in
CSF-1-differentiated PBMC cells, a further treatment with IL-32γ or
CSF-1 activated MAPK such as p38, JNK and ERK1/2, while the
IL-32γ/CSF-1 combination induced a more sustained MAPK
activation and increased survival. Moreover, IL-32γ induced the
production of IL-6, GROa and IL-8, as well as the expression of the
costimulatory molecule CD80, at higher levels than CSF-1. These
IL-32γ-induced M1-like characteristics were unaffected by the
cotreatment with CSF-1. Moreover, IL-32γ–treated macrophages
showed rather low expression levels of CD86, another M1 marker,
compared with CSF-1-treated macrophages. On the other hand, M2-
like characteristics, including phagocytic activity, and CD14 and
CD163 expression were significantly upregulated in IL-32γ-treated
compared with CSF-1-treated macrophages and CSF-1/IL-32γ
cotreatment further upregulated the expression of CD14 and CD163.
These results suggest that IL-32γ induces macrophages with both M1
and M2 phenotypes, and that CSF-1 preferentially accelerates the M2
polarization induced by IL-32γ. Thus, CSF-1 seems to have either
additive or inhibitory effects on IL-32γ action as far as the M1 and M2
phenotypes are concerned [54].
Role of CSF-1R in the Polarization of Macrophages in
Inflammatory and Autoimmune Diseases
CSF-1R signaling plays important roles in inflammatory/
immunitary diseases, including systemic lupus erythematosus,
arthritis, atherosclerosis and obesity [57-59]. Importantly, CSF-1
concentration in serum may be increased in several chronic diseases
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[58] where an autocrine mechanism may also be involved [60].
Macrophage populations elicited by CSF-1R signaling are associated
with, and may exacerbate, a broad spectrum of inflammatory and
autoimmune diseases. On the other hand, macrophages can also
contribute to immunosuppression, disease resolution and tissue repair
[12,28].
Pro-inflammatory role of CSF-1R signaling
Besides inflammation-associated organ dysfunction, patients with
infections and autoimmune diseases suffer from sickness behavior
syndrome (SBS), which is characterized by fatigue, depression, weight
loss and reduced social activities [61]. The interactions of CD40 with
its ligand (CD40L) play a major role in the development of the host
response to infectious pathogens and of chronic inflammatory diseases
including autoimmune liver diseases. CD40 mediates T cell-dependent
B cell responses, enhances the expression of MHC and costimulatory
molecules on DC and macrophages and elicits the production of
proinflammatory cytokines including TNFα, IL-1β, IL-6, typical M1
cytokines, and IL-8 and GM-CSF and CSF-1 [62]. Treatment of mice
with the CSF-1R-blocking monoclonal antibody (mAb) M279 protects
from CD40-induced SBS (i.e., prevents the decrease of motional
activity and body weight) while increasing IL-10 (M2 cytokine)
production rather than decreasing the amount of the proinflammatory
cytokines such as the M1 cytokines TNFα and IL-6. However, CSF-1R
blockade did not impair CD-40-induced splenomegaly and hepatitis.
Protection from SBS upon CSF-1R inhibition is mediated by the
induction of IL-10 expression in inflammatory monocytes, because
anti-CSF-1R mAb failed to prevent the development of CD40-induced
SBS in IL-10-/- mice. This study thus indicates that CSF-1R blocking
might be a useful tool to prevent SBS, which impairs quality of life in
patients, although the overall course of chronic inflammation would
not be affected. Moreover, the above results indicate that targeting
CSF-1R may lead to a conversion of inflammatory monocytes to a
mixed pro-inflammation/pro-resolution cell type [63]. This is in
keeping with the fact that the prolonged treatment of mice with the
M279 mAb allows the depletion of CSF-1R-expressing resident tissue
macrophages in liver, lung broncho-alveolar space, intestinal tract,
pancreas and kidney without ablating the development of
inflammatory monocytes [40].
Altered macrophage behavior is central to the pathogenesis of
chronic obstructive pulmonary disease (COPD) [64]. Serum amyloid
A (SAA) is expressed locally in chronic inflammatory conditions such
as COPD, where macrophages that do not correspond to the classic
M1/M2 paradigm also accumulate. Differentiation of human
monocytes with CSF-1 and GM-CSF together with SAA stimulates the
M1 cytokines IL-1 and IL-6 concurrently with the M2 markers CD163
and IL-10 more efficiently than in the absence of SAA. Experiments
performed in vivo showed an increase of the inflammatory CD11chigh/
CD11bhigh population following SAA challenge. Inhibition of CSF-1R
by intranasal pretreatment with the AFS98 anti-CSF-1R mAb markedly
reduces the emergence of this population. These results indicate
CSF-1R targeting as a possible tool to prevent this emergence and a
novel approach to treat chronic inflammatory conditions associated
with persistent SAA expression [65].
Many individuals with human immunodeficiency virus (HIV)
infection develop varying degrees of cognitive impairment, collectively
termed HIV-associated neurocognitive disorders. Although the
pathogenesis of these disorders is not completely understood, activated
microglia and macrophages infiltrating CNS are believed to play a
prominent role in its development and/or progression [66]. CSF-1 is
detectable in cerebrospinal fluid of HIV-infected patients and is
believed to support virus production and disease progression [67].
Macrophages accumulate in the perivascular cuffs and within nodular
lesions, either lesions being among the histological hallmarks of both
HIV-induced and simian immunodeficiency virus (SIV)-induced
encephalitis (HIVE and SIVE, respectively) [68]. A recent study
identified macrophages as the main source of CSF-1 in SIV-infected
rhesus macaques, a relevant animal model for HIV-associated
neuropathogenesis [69]. In the same study, IL-34, the alternative ligand
of CSF-1R, was found mostly associated with cells scattered in the
parenchyma, rather than with cells accumulating around blood vessels
and within nodular lesions [69]. In another paper, the same authors
explored the potential relationship of CSF-1 and/or IL-34 with M2
activation in SIVE [70]. They found that CD163, a marker of a subclass
of M2 macrophages [7], is upregulated in brain of SIV-infected rhesus
macaques with SIVE. Moreover, in SIVE brain, accumulating CSF-1-
positive macrophages are also CD163+, indicating that they are a
source of CSF-1 in SIVE. By contrast, CD163 expression in
parenchyma does not colocalize considerably with CSF-1, but does
with IL-34. In addition, in the frontal grey matter, the neurons also
express CSF-1 and IL-34, and CSF-1 expression is significantly
decreased in SIV and even more in SIVE. In vitro experiments showed
that treatment with the CSF-1R inhibitor GW2580 decreases the
number of CD163+ cells, thus demonstrating that CSF-1R signaling,
via either of its ligands, may contribute to sustained M2 activation in
brain in SIV infection and SIVE [70]. On the basis of the above results,
the authors conclude that, upon CSF-1 ligation, CSF-1R signaling plays
an important role in the pathogenesis of HIV-associated
neurodegenerative disease, while additional studies are needed to
elucidate the potentially divergent roles of CSF-1 and IL-34. IL-34,
indeed, may contribute to M2 activation/polarization in the brain, but
may also promote neuronal survival.
Anti-inflammatory role of CSF-1R signaling
Renal tubule epithelia represent the primary site of damage in acute
kidney injury (AKI), a process initiated and propagated by
macrophage infiltration [71]. Using two murine models of AKI, based
on ischemia/reperfusion (I/R)-induced injury or diphtheria toxin
(DT)-induced selective proximal tubule injury, Zhang and colleagues
examined the role of macrophages/DC (F4/80hi) in the recovery
following AKI. In both models, macrophage/DC depletion during the
recovery phase increased functional and histological injury and
delayed regeneration. After I/R-induced AKI, there was an early
increase of inflammatory (M1) monocytes (as detected based on iNOS
expression), followed by the accumulation of renal macrophages/DC
with a wound-healing (M2) phenotype (increase of Arg1). By contrast,
DT-induced AKI only generated an increase of M2 cells. Genetic or
pharmacologic (GW2580) inhibition of CSF-1R blocked
macrophage/DC proliferation, decreased M2 polarization and
inhibited recovery. These findings demonstrated that CSF-1R-mediated
expansion and polarization of resident renal macrophages/DC is an
important mechanism mediating renal tubule epithelial regeneration
after AKI [72]. The same authors, in a very recent study, confirmed and
further characterized the protective role of CSF-1R signaling following
AKI. In both models of AKI, selective deletion of CSF-1 expression in
the proximal tubule determined decreased M2 polarization, delayed
functional and structural recovery and increased tubulointerstitial
fibrosis [73]. Therefore, CSF-1, that is abundantly produced in the
kidney and specifically at the proximal tubule, stimulates renal
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epithelial cell proliferation directly after AKI [74], but is also an
important mediator of macrophage/DC polarization and recovery
from AKI [73].
Role of CSF-1R in the Polarization of Macrophages in
the Tumor Context
Tumor-associated macrophages (TAM) are the predominant
leukocytes infiltrating solid tumors and can represent up to 50% of the
tumor mass. TAM can exert dual influence of cancer depending on the
activation state, with classically activated (M1) and alternatively
activated (M2) cells generally exerting antitumor and pro-tumor
functions, respectively [75,76]. These are extremes in a continuum of
polarization states. It is now recognized that TAM, that are recruited
by CSF-1 and MCP-1/CCL2, represent the most abundant
immunosuppressive cell population in the tumor microenvironment
[77]. A number of cell types within the tumor microenvironment as
well as tumor cells produce CSF-1 [78] and circulating CSF-1 may
increase in several cancer types including that of breast, endometrium
and ovary [79-81].
Macrophage infiltration in tumors has been identified as an
independent factor predictive of poor prognosis for several cancer
entities, colorectal cancer (CRC) being probably the only exception
because in this cancer TAM density is significantly associated with
enhanced overall survival [76,82]. These diverse anti-tumoral or
tumor-promoting activities of TAM are likely promoted by distinct
TAM subpopulations, linked to different intratumoral
microenvironments [76,83]. Indeed, molecularly and functionally
distinct TAM subpopulations coexist in tumors, depending on cancer
type, stage of tumor progression and location within the tumor tissue
[4]. This TAM heterogeneity likely reflects the inherent plasticity of
macrophages in response to microenvironmental triggers. The relevant
role of CSF-1R in TAM with respect to cancer progression is well
acknowledged [12, 27, 84-86]. More importantly, CSF-1/CSF-1R
blocking may represent the only truly selective approach to manipulate
macrophages in cancer patients. Accordingly, strong reductions of
TAM number have been reported in various tumor models upon
blocking of CSF-1/CSF-1R signaling using mAb targeting either CSF-1
or the extracellular domain of CSF-1R, or using chemical inhibitors of
CSF-1R tyrosine kinase activity and thereby the downstream signaling
[84].
Pro-tumoral activity of CSF-1R signaling in TAM
The presence of extensive TAM infiltration in clear cell renal cell
carcinoma (ccRCC) microenvironment contributes to cancer
progression and metastasis by stimulating angiogenesis, tumor growth,
and cellular migration and invasion [87]. Immunostaining of human
ccRCC specimens showed a correlation between the number of
CD163+ M2 macrophages and age, sex, nuclear grade and TNM
classification [88]. On the other hand, high levels of CD163+ cell
infiltration were significantly associated with poor clinical prognosis in
univariate but not multivariate analysis. Culture supernatants from
ccRCC cell lines induced M2 polarization of macrophages, as indicated
by the increased expression of CD163 and IL-10, two M2 typical
markers, following LPS treatment. Stronger results were obtained when
direct interaction of ccRCC cells and macrophages was allowed.
Primary ccRCC cells consistently express surface CSF-1. Genetic or
pharmacological inhibition of CSF-1R (obtained using specific siRNA
or GW2580, respectively) or block of CSF-1 binding to CSF-1R
suppressed macrophage IL-10 production induced by ccRCC cells.
These results indicate that the signaling initiated by the cross-talk
between ccRCC cells and macrophages is mediated by the CSF1/
CSF1R pair. Furthermore, the block of CSF-1R signaling and the
consequent reversion of immunosuppressive conditions emerges as a
promising approach for anticancer therapy in patients with ccRCC
[88].
Although macrophages are endowed with a high level of plasticity,
within the tumor microenvironment they mostly facilitate tumor
development rather than regression, mainly because they function as
immunosuppressive cells. Along this line, skewing of monocyte
differentiation from DC to macrophages has been proposed to
contribute to immunosuppression [89]. In a study performed to
investigate on the possibility that TAM could be redirected toward a
DC-like phenotype, it was found that treatment in vitro with GM-CSF,
which is able to induce maturation of myeloid cells toward a DC
phenotype [90], does not change the expression of M1-type (IL-1β,
TNFα, and CXCL10) or M2-type (CCL22, CCL17, IL-10, and CD206)
markers in F4/80high and CD11bhigh TAM isolated from abdominal
tumors established by inoculating the colon carcinoma cell line
MCA38 [91]. Moreover, the combined treatment of TAM with GM-
CSF and CSF-1R-targeting siRNA did not alter the expression pattern
of M1/M2 marker but was able to induce the expression of STAT1,
STAT5 and STAT6, which are usually expressed by DC [92]. These
findings indicated that GM-CSF administration together with a CSF-1-
inhibiting treatment could not redirect TAM to a monocyte-derived
DC-like phenotype, as determined by M1/M2 marker expression, but
was able to modify cell signaling pathways towards a DC-like pattern
[91].
Glioblastoma (GBM), the most aggressive form of glioma, has an
invariably unfavorable prognosis, as patients respond minimally to
current therapies, including surgery, radiation and chemotherapy.
TAM are associated with high tumor grade and poor prognosis in
gliomas, possibly because, under the influence of glioma cells,
microglia creates an immunosuppressive microenvironment which
promotes glioma growth [93]. In a mouse model that recapitulates
human proneural GBM, in vivo CSF-1R inhibition using the CSF-1R
inhibitor BLZ945 significantly increased survival and induced
regression of established tumors [94]. However, these effects were not
associated with TAM depletion. Rather, GBM-secreted factors,
including GM-CSF and IFNγ, facilitated TAM survival in the context
of CSF-1R inhibition and resulted in a repolarization from pro-
tumoral M2 to a highly phagocytic M1 phenotype. These results
identify TAM as a promising therapeutic target for proneural gliomas
and establish the translational potential of CSF-1R inhibition for GBM
therapy [94].
Despite the fact that a role for CSF-1/CSF-1R signaling and TAM in
breast cancer progression has been well established [27], attempts to
obtain the therapeutic depletion of macrophages from tumors using as
single agents mAb or chemical inhibitors targeting CSF-1 or CSF-1R
were disappointing [36,95]. Nevertheless, the administration to mice of
inhibitors of CSF-1R signaling in combination with standard-of-care
chemotherapy slows down the growth of primary tumors significantly
and reduces pulmonary metastasis [36]. On the basis of these data,
phase 1 and 2 clinical studies combining the CSF-1R inhibitor
PLX3397 with chemotherapy are currently under way. The mouse
mammary tumor virus/polyoma middle T (MMTV/PyMT) transgenic
model of luminal B-type mammary carcinoma was used to shed light
on the mechanisms by which the CSF-1/CSF-1R pathway and
macrophages repress response to cytotoxic therapy in mammary
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carcinoma. It was found that the anti-CSF1 5A1 blocking mAb, alone
or in combination with paclitaxel (PTX), depleted mammary tumors
from CD11b+F4/80+MHCII+Ly6C- macrophages [96]. Following anti-
CSF-1 mAb treatment, IL-10 expression was markedly reduced and it
turned out to be mostly produced by macrophage cells in MMTV/
PyMT tumors. Moreover, the block of IL-10R by specific antibodies
improves response to PTX, in terms of tumor volume in MMTV/
PyMT mice, or of survival in mice following orthotopic
transplantation of MMTV/PyMT-derived tumors, or lung metastasis
following treatment with IgG1, anti-CSF-1 mAb, anti-IL-10R mAb,
PTX, or a combination thereof and similarly to what observed by anti-
CSF-1mAb/PTX. Improved response to chemotherapy was CD8+Tcell-
dependent, but IL-10 did not directly suppress CD8+Tcells or alter
macrophage polarization. Instead, IL-10R block increased in
intratumoral DC the expression of IL-12, which was necessary for
improved outcomes. These data indicate that macrophages infiltrating
mammary carcinomas are a significant source of IL-10, which in turn
suppresses IL-12 production by DC and thereby limits T-cytotoxic
responses during chemotherapy. These data identify a CSF-1/IL-10/
IL-12 axis which is suitable for therapeutic targeting [96].
In another study, it was identified a new mechanism that allows
macrophages to maintain locally restrained and smoldering
inflammation, which is required in angiogenesis and metastasis.
Indeed, it was found that IL-34- and CSF-1-differentiated
macrophages exhibit most of the phenotypic (i.e., CD14high
CD163high IL-10high IL-12low CD86low) and functional characteristics
(i.e., low T-cell costimulatory properties, inhibition of activated
effector T-cell functions) of TAM isolated from human ovarian cancer.
Moreover, IL-34- and CSF-1-differentiated TAM in human ovarian
cancer switch memory Tcells into Th17 cells via membrane IL-1α [97].
A number of papers from Corbí’s group identified several markers
possibly associated to CSF-1-, but not GM-CSF-, differentiated
macrophages within the tumor context. Indeed, it was found that
CSF-1-, but not GM-CSF-differentiated macrophages express folate
receptor beta (FRβ, encoded for by FOLR2) and display folate binding
and internalization ability. Therefore, CSF-1 promotes the expression
of a functional FRβ protein, which was therefore proposed to be a
further marker of CSF-1-differentiated M2 macrophages. Consistent
with a possible role of FRβ in vivo, FRβ is functionally expressed in
IL-10 mRNA-expressing CD14+ CD68+ CD163+ melanoma TAM.
Other cytokines commonly released by tumors, including IL-6 alone
and IL-10 in combination with CSF-1, upregulate FOLR2 mRNA
expression. Moreover, conditioned media from several cancer cell lines
are able to induce the expression of FRβ. Incubation with an anti-CSF1
blocking antibody greatly reduced the upregulation of FOLR2 mRNA
promoted by ascitic fluid from breast carcinoma or by conditioned
medium from tumor-associated fibroblasts or JEG-3 tumor cells.
Therefore, CSF-1 is a major determinant for FRβ expression on human
macrophages and contributes, alone or in combination with other
cytokines, to FRβ cell surface expression on TAM [98]. These results
identified a new possible marker for TAM and, more importantly,
provided a possible rationale for folate-conjugated drugs in cancer
therapy approaches [99]. In another paper, the same authors showed
that the heme regulatory molecules CD163 and HO-1 are
preferentially expressed by CSF-1-differentiated (M2) macrophages
with respect to GM-CSF-differentiated (M1) macrophages [100]. They
also showed that M1 macrophages secreted large amounts of
functional activin A that promotes the expression of M1 (GM-CSF-
differentiated) markers, impairs the acquisition of M2 (CSF-1-
differentiated) markers, and down-regulates the production of IL-10.
These results indicate that activin A contributes to macrophage
polarization and shapes the inflammatory behavior of macrophages
[101]. More recently, it was also found that CSF-1-differentiated
macrophages obtained from human PBMC express and produce
CCL2, while GM-CSF-differentiated macrophages express CCL2R.
CD14+ TAM isolated from ascitic fluid of different types of cancer
express CCL2 at an even higher extent that CSF-1-differentiated
macrophages [102]. Taken together, the above-described results
support further a protumoral activity of CSF-1R signaling.
Anti-tumoral activity of CSF-1R signaling in TAM
Despite the abundant literature on the many pro-tumoral functions
of TAM in several types of cancer, their role in CRC is controversial.
Some studies indicated that macrophages in CRC appear to have
antitumor activity and are associated with improved disease-free
survival. On the contrary, other studies provided evidence that a
massive macrophage infiltration is correlated with tumor progression,
growth and disease aggressiveness [103]. Nevertheless, we could not
find any literature evidence of a role of CSF-1R in macrophage
polarization in the context of CRC or other cancer types.
Conclusive Remarks in View of Drugging CSF-1R to
Target Macrophage Polarization
Targeting CSF-1R signal could be undoubtedly beneficial in many
conditions, including several types of cancer and chronic
inflammations [12,28,86]. The block of CSF-1R may represent a truly
selective approach and several CSF-1R signaling inhibitors have been
developed [86,104]. However, several points are worth to be discussed,
especially with respect to the role of CSF-1R signaling in macrophage
polarization.
First, CSF-1R-elicited signals are important for several homeostatic
mechanisms, so that their prolonged inhibition might be generally
detrimental, although necessary for the treatment of specific diseases
such as cancers or chronic inflammations. For example, CSF-1 is a
main regulator of osteoclast differentiation, as evidenced by the
osteopetrotic phenotypes of CSF-1- or CSF-1R-deficient mice [13,22].
Therefore, different ways to inhibit CSF-1R-signalling should be used
to achieve different outcomes. In this respect, using antibodies that
specifically prevent the binding to CSF-1R of CSF-1 but not IL-34, or
vice versa, would block only specific effects. In this respect, it is worth
pointing out that anti-CSF-1R mAb that impair CSF-1 but not IL-34
binding to CSF-1R have been identified [44]. These differences have
been explained by supposing that IL-34 and CSF-1 bind overlapping
yet different domains of CSF-1R. For example, it has been reported
that either CSF-1- or IL-34-differentiated macrophages exhibit most of
the phenotypic and functional characteristics of TAM isolated from
human ovarian cancer [105]. However, IL-34 and CSF-1-differentiated
macrophages may have different biological activities [44]. Another
approach to avoid extreme toxicities due to systemic and persistent
CSF-1R inhibition led to the development of the new H27K15 anti-
CSF-1R monoclonal antibody, that, differently from other anti-CSF-1R
mAb, does not compete with ligand binding and exhibits different
effects on signal transduction and cellular trafficking [41]. First, the
H27K15 mAb downregulates osteoclast differentiation and activity,
which could block metastasis-induced bone degradation. Second, it
inhibits monocyte differentiation into CD163+CD64+ M2-polarized
suppressor macrophages, rather driving their differentiation towards
CD14−CD1a+ DC. Third, this antibody differs from other anti-CSF-1R
mAb by affecting monocyte survival only marginally. Therefore, the
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H27K15 mAb shows interesting properties that may make it suitable
for clinical uses in cancer therapy [41].
On the other hand, in some specific context, the inhibiting strategy
(antibodies versus chemical inhibitors) could be chosen based on the
kind of molecule preferred in relation to the tissue to be targeted.
Importantly, small molecule inhibitors that are able to cross the blood-
brain barrier have been developed (Table 1). Referring to small
molecule inhibitors that act at the level of CSF-1R kinase activity, they
would also prevent ligand-independent CSF-1R activation, which may
be induced via the crosstalk with other signaling pathways [21].
However, mAb that are able to prevent CSF-1R dimerization have also
been developed; these mAb are also able to prevent ligand-
independent CSF-1R activation if it involves receptor dimerization
[106]. Another important fact that should be taken into account when
choosing the inhibiting treatment is that CSF-1 is cleared from serum
by receptor-mediated endocytosis [60], so that the use of antibodies
which prevent CSF-1 to CSF-1R binding causes massive elevation in
circulating CSF-1. A similar elevation may also result from the killing
of CSF-1R-expressing cells. On the other hand, the increase in
circulating CSF-1 is not supposed to occur if kinase inhibitors are
added, unless they are deadly (see above), because receptor-mediated
internalization does not require CSF-1R kinase activity.
Another possible approach to target disease-associated
macrophages would be to shift a macrophage population towards a
more appropriate phenotype. Indeed, skewing of monocyte
differentiation from DC to macrophages has been proposed to
contribute to tumor-induced immunosuppression [89]. For example, it
has been reported that pharmacological [107] or genetic [91]
inhibition of CSF-1R, as well as that based on anti-CSF-1R blocking
mAb [41], can change the function or morphology of macrophages
and induce DC-like characteristics. Moreover, mounting evidence
from a number of different studies in vivo and in vitro has generally
indicated that identifying the activated states of macrophages and
targeting the macrophage polarization from M1 to M2 or vice versa
might represent a novel diagnostic or therapeutic strategy for a
number of diseases [15]. In these respect, several examples of
modulation of macrophage plasticity have been described in this
review.
Inhibitor Type of molecule Target Other targets (IC50, nM) Notes Reference
PLX3397 Small-molecule inhibitor CSF-1R CSF-1R (20)
KIT (10)
Crosses blood-brain barrier [36]
GW2580 Small-molecule inhibitor CSF-1R [37]
BLZ945 Small-molecule inhibitor CSF-1R Crosses blood-brain barrier [38]
5A1 Blocking mAb antibody CSF-1 [39]
M279 Blocking mAb antibody CSF1-R [40]
H27K15 Blocking mAb antibody CSF-1R Impairs receptor dimerization [41]
AFS98 Blocking mAb antibody CSF-1R [42]
12-2D6 Blocking mAb antibody CSF-1R Blocks either CSF-1 or IL-34 binding [44] [43]
2-4A5 Blocking mAb antibody CSF-1R Blocks CSF-1 but not IL-34 binding [44] [43]
mAb: Monoclonal Antibody; CSF-1: Colony Stimulating Factor-1; CSF-1R: CSF- 1 Receptor
Table 1: CSF-1R signaling inhibitors cited in the text.
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